Compare PAYO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | PTGX |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | 2540 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 5.2B |
| IPO Year | N/A | 2016 |
| Metric | PAYO | PTGX |
|---|---|---|
| Price | $4.79 | $98.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $7.69 | ★ $106.67 |
| AVG Volume (30 Days) | ★ 4.1M | 811.3K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | $867.86 |
| Revenue Next Year | $9.77 | N/A |
| P/E Ratio | $30.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.08 | $39.60 |
| 52 Week High | $7.67 | $105.69 |
| Indicator | PAYO | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 56.73 |
| Support Level | $4.32 | $76.63 |
| Resistance Level | $4.86 | $100.00 |
| Average True Range (ATR) | 0.20 | 4.71 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 59.33 | 53.74 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.